The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer

Ana Regina de Abreu; Ken Op de Beeck; Pierre Laurent-Puig; Valerie Taly; Leonor Benhaim

doi:10.3390/cancers15041284

The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer

Ana Regina de Abreu, Ken Op de Beeck, Pierre Laurent-Puig, Valerie Taly, Leonor Benhaim

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

4 Citations (Scopus)

Résumé

Colorectal cancer (CRC) is the third most common cancer type worldwide, with over 1.9 million new cases and 935,000 related deaths in 2020. Within the next decade, the incidence of CRC is estimated to increase by 60% and the mortality by 80%. One of the underlying causes of poor prognosis is late detection, with 60 to 70% of the diagnoses occurring at advanced stages. Circulating cell-free DNA (ccfDNA) is probably the most promising tool for screening, diagnosis, prediction of therapeutic response, and prognosis. More specifically, the analysis of the tumor fraction within the ccfDNA (circulating tumor DNA, ctDNA) has great potential to improve the management of CRC. The present review provides an up-to-date and comprehensive overview of the various aspects related to ctDNA detection in CRC.

langue originale	Anglais
Numéro d'article	1284
journal	Cancers
Volume	15
Numéro de publication	4
Les DOIs	https://doi.org/10.3390/cancers15041284
état	Publié - 1 févr. 2023

Accès au document

10.3390/cancers15041284

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{441e09a336d543f78adb4b10f7c3353d,

title = "The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer",

abstract = "Colorectal cancer (CRC) is the third most common cancer type worldwide, with over 1.9 million new cases and 935,000 related deaths in 2020. Within the next decade, the incidence of CRC is estimated to increase by 60% and the mortality by 80%. One of the underlying causes of poor prognosis is late detection, with 60 to 70% of the diagnoses occurring at advanced stages. Circulating cell-free DNA (ccfDNA) is probably the most promising tool for screening, diagnosis, prediction of therapeutic response, and prognosis. More specifically, the analysis of the tumor fraction within the ccfDNA (circulating tumor DNA, ctDNA) has great potential to improve the management of CRC. The present review provides an up-to-date and comprehensive overview of the various aspects related to ctDNA detection in CRC.",

keywords = "circulating tumor DNA, colorectal cancer, management, treatment",

author = "{de Abreu}, {Ana Regina} and {Op de Beeck}, Ken and Pierre Laurent-Puig and Valerie Taly and Leonor Benhaim",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = feb,

day = "1",

doi = "10.3390/cancers15041284",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

number = "4",

}

TY - JOUR

T1 - The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer

AU - de Abreu, Ana Regina

AU - Op de Beeck, Ken

AU - Laurent-Puig, Pierre

AU - Taly, Valerie

AU - Benhaim, Leonor

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Colorectal cancer (CRC) is the third most common cancer type worldwide, with over 1.9 million new cases and 935,000 related deaths in 2020. Within the next decade, the incidence of CRC is estimated to increase by 60% and the mortality by 80%. One of the underlying causes of poor prognosis is late detection, with 60 to 70% of the diagnoses occurring at advanced stages. Circulating cell-free DNA (ccfDNA) is probably the most promising tool for screening, diagnosis, prediction of therapeutic response, and prognosis. More specifically, the analysis of the tumor fraction within the ccfDNA (circulating tumor DNA, ctDNA) has great potential to improve the management of CRC. The present review provides an up-to-date and comprehensive overview of the various aspects related to ctDNA detection in CRC.

AB - Colorectal cancer (CRC) is the third most common cancer type worldwide, with over 1.9 million new cases and 935,000 related deaths in 2020. Within the next decade, the incidence of CRC is estimated to increase by 60% and the mortality by 80%. One of the underlying causes of poor prognosis is late detection, with 60 to 70% of the diagnoses occurring at advanced stages. Circulating cell-free DNA (ccfDNA) is probably the most promising tool for screening, diagnosis, prediction of therapeutic response, and prognosis. More specifically, the analysis of the tumor fraction within the ccfDNA (circulating tumor DNA, ctDNA) has great potential to improve the management of CRC. The present review provides an up-to-date and comprehensive overview of the various aspects related to ctDNA detection in CRC.

KW - circulating tumor DNA

KW - colorectal cancer

KW - management

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85149144277&partnerID=8YFLogxK

U2 - 10.3390/cancers15041284

DO - 10.3390/cancers15041284

M3 - Review article

AN - SCOPUS:85149144277

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 4

M1 - 1284

ER -